Nomura Cuts JD HEALTH TP to HKD51; 4Q Revenue Outlook Weakens but Margin Expansion May Persist
AASTOCKS News·
- Nomura reported mixed 3Q results for JD HEALTH with revenue rising 17% YoY to RMB 20 billion and non-IFRS operating profit increasing 14% YoY to RMB 1.6 billion.
- Management lowered its full-year 2026 revenue growth guidance to mid-teens due to regulatory reviews and recalls, prompting Nomura to lower its 4Q revenue growth expectation to around 10%.
- Nomura maintained a Buy rating on JD HEALTH while cutting its target price from HKD 60 to HKD 51 and adjusting future revenue and profit forecasts.
